Advanced search
Start date

Comparative study on the effects of sildenafil and tadalafil in advanced pulmonary arterial hypertension associated with congenital heart defects (Eisenmenger syndrome)


Sildenafil (20 mg t.i.d.) and tadalafil (40 mg, single daily dose) are oral therapies approved for pulmonary arterial hypertension (PAH). Because there are no comparative studies using these drugs, the present study is aimed at comparing their effects in subjects with PAH associated with congenital heart disease (so called Eisenmenger syndrome). The study will be randomized, and performed over six months. The impact of treatments on the physical capacity will be tested by the six-minute walk test, and pulse oxymetry. Health-related quality of life will be analyzed as well. The possible impact of both phosphodiesterase-5 inhibitors on endothelial and platelet dysfunction will be analyzed by measuring the circulating levels of von Willebrand fact, tissue-type plasminogen activator, Thrombomodulin, P-selectin, beta-thromboglobulin and soluble CD40-L. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
CLAVE, MARIANA M.; MAEDA, NAIR Y.; THOMAZ, ANA M.; BYDLOWSKI, SERGIO P.; LOPES, ANTONIO A.. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. CONGENITAL HEART DISEASE, v. 14, n. 2, p. 246-255, . (12/10739-0)
CLAVE, MARIANA M.; MAEDA, NAIR Y.; CASTRO, CLAUDIA R. P.; BYDLOWSKI, SERGIO P.; LOPES, ANTONIO A.. Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study. PULMONARY CIRCULATION, v. 7, n. 3, p. 635-642, . (12/10739-0)

Please report errors in scientific publications list using this form.